Video

The FDA's "Platform" Provision: An Emerging Debate Among Regulators

Source: Advancing RNA

Though the mRNA industry is particularly excited about the possibilities of the FDA’s yet-to-be-clarified “Platform Provision,” ReciBioPharm’s Melanie Cerullo and Arcturus’ Ye Zhang “spill the tea” about a recent discussion between regulators that suggest differences in opinion are emerging around how the industry should be defining/approaching “the platform."

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Advancing RNA? Subscribe today.

Subscribe to Advancing RNA X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Advancing RNA

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)